Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, Australia.
South Western Sydney Clinical School, University of New South Wales Sydney, Liverpool, Sydney, Australia.
Liver Int. 2023 Jan;43(1):69-76. doi: 10.1111/liv.15372. Epub 2022 Aug 8.
Achieving Hepatitis B e antigen seroconversion (HBeAg SC) at an earlier age confers a better prognosis. We examined baseline and post-partum factors associated with HBeAg SC after pregnancy. We developed a tool, the SydPregScore, to estimate the likelihood of HBeAg SC in the years after pregnancy.
A retrospective analysis of an HBeAg-positive pregnant cohort was conducted. Variables including baseline age, parity, alanine aminotransferase level, HBV viral load, quantitative HBsAg, use of antiviral therapy and post-partum flare were collected. Univariate and multivariate Cox regression analyses to determine predictors of HBeAg SC and develop a predictor score were performed.
We analysed HBeAg SC rates in 220 pregnancies to 149 HBeAg-positive women from 2006 to 2019. At baseline, their median age was 33 (IQR 29-37), ALT 23 U/L (IQR 17-33) and viral load 8 log IU/mL (IQR 6.3-8.2 log IU/mL). The majority (133/198, 67.2%) received short-course antiviral therapy to prevent mother-to-child transmission, and 109/192 (56.8%) had a post-partum flare. HBeAg SC occurred in 74/220 (33.6%) after pregnancy (median follow-up 814 days, IQR 405-1531). Multivariate analysis identified baseline viral load <8 log IU/mL (HR 2.426 [1.224-4.809], p = .011), baseline ALT ≥2 ULN (HR 2.726 [1.299-5.721], p = .008) and age <35 (HR 2.859 [1.255-6.513], p = .012) to be positive predictors of HBeAg SC. The 'SydPreg Score' estimated the probability of HBeAg SC at 2000 days as 10%, 30%, 70% and 80% for 0, 1, 2, and 3 predictors respectively.
The SydPreg Score allows the prediction of HBeAg SC in the years after pregnancy. Even in those without elevated ALT, age <35 and viral load <8 log IU/mL can identify women with a good chance of subsequent HBeAg SC. Those without a chance may benefit from viral suppression.
在较早的年龄实现乙型肝炎 e 抗原血清学转换(HBeAg SC)可带来更好的预后。我们研究了与妊娠后 HBeAg SC 相关的基线和产后因素。我们开发了一种工具,即 SydPregScore,以估计妊娠后数年 HBeAg SC 的可能性。
对 HBeAg 阳性孕妇队列进行回顾性分析。收集了包括基线年龄、产次、丙氨酸氨基转移酶(ALT)水平、HBV 病毒载量、定量 HBsAg、抗病毒治疗的使用和产后发作等变量。进行单变量和多变量 Cox 回归分析,以确定 HBeAg SC 的预测因素并开发预测评分。
我们分析了 2006 年至 2019 年间 149 名 HBeAg 阳性女性的 220 次妊娠中 HBeAg SC 的发生率。基线时,中位年龄为 33 岁(IQR 29-37),ALT 23 U/L(IQR 17-33),病毒载量为 8 log IU/mL(IQR 6.3-8.2 log IU/mL)。大多数(133/198,67.2%)接受了短期抗病毒治疗以预防母婴传播,109/192(56.8%)出现了产后发作。妊娠后 HBeAg SC 发生于 74/220(33.6%)例患者(中位随访 814 天,IQR 405-1531)。多变量分析确定基线病毒载量<8 log IU/mL(HR 2.426 [1.224-4.809],p =.011)、基线 ALT ≥2 ULN(HR 2.726 [1.299-5.721],p =.008)和年龄<35 岁(HR 2.859 [1.255-6.513],p =.012)是 HBeAg SC 的阳性预测因素。“SydPreg 评分”估计在 2000 天时 HBeAg SC 的概率分别为 0、1、2 和 3 个预测因素时的 10%、30%、70%和 80%。
SydPregScore 可预测妊娠后 HBeAg SC 的发生。即使 ALT 不升高,年龄<35 岁且病毒载量<8 log IU/mL 也可以识别出具有良好后续 HBeAg SC 机会的女性。没有机会的患者可能受益于病毒抑制。